More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial and the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced) showed that treatment with SGLT2 inhibitors significantly reduced the risk of worsening heart failure or death from cardiovascular causes, regardless of the presence or absence of type 2 diabetes4,5. This evidence concerns the gene SLC5A2 and heart failure.